Transforming healthcare, the evolution of the global radiology market suggests that the global market is projected to reach market size of USD 73.18 Billion by 2029.
Lifescience
Active pharmaceutical ingredients, which are core to the manufacturing of effective and safe essential drugs, are increasingly adopted across the globe.
Active pharmaceutical ingredient is the part of drug used in medicament along with Diluents. Excipient is a formulated Compound which is used to increase weight and improve the content uniformity. It is also known as a diluent, such as lactose monohydrate, and sugar alcohols like mannitol, xylitol, and sorbitol etc.
The global Active Pharmaceutical Ingredients market is highly concentrated and competitive. Pfizer, The Cipla, Novartis, Mylan NV, Sun Pharmaceuticals are the prominent vendors in the industry. Over the past decade, several companies have engaged in merger and acquisitions to establish their presence in the industry. Mergers and acquisitions offers several benefits, like, better access to procuring raw materials, distribution and R&D and are largely driven by the consolidation. Manufacturer must always keep pace with the latest industry regulations for the manufacturing Active Pharmaceutical ingredients to avoid penalties with criminal sanctions. The demand for APIs is expected to accelerate because the increase in the geriatric population and increase in awareness for better healthcare. Quality of active pharmaceutical ingredients in a drug has a direct effect on the safety or efficacy of the drugs that are responsible for beneficial health effects on consumers. The most common example of active pharmaceutical ingredient is the acetaminophen and diclofenac containing analgesic drugs.. Excipients must be non-toxic and physically and chemically inert in combination with active pharmaceutical ingredients. Active pharmaceutical ingredients are made not only of a single chemical compound from the raw material but Active Pharmaceutical Ingredients contain several chemical compounds. The intermediate chemical compound which is in the process of becoming active pharmaceutical ingredients from a raw material is called an intermediate.
In North America, Active pharmaceutical Ingredients market is likely to be driven by the adoption of biologics in management, various biological therapeutics, expiration of patent drugs and the outsourcing growth etc. dominated the share of North America market due to growing incidence of severe chronic disease. Ultimately increase in demand of Biological Active Pharmaceutical Ingredients. Raising the number of regulatory approval and increase the R & D, investment moving towards the North America market has increase. In North America according to the country like USA, Canada, and Mexico, Most of the Active pharmaceutical ingredients are manufacture by USA market. USA is doing lot of investments on the advance technology for the manufacturing of Active Pharmaceutical Ingredients.
The Middle East & Africa active pharmaceutical ingredient market is projected to boom in the upcoming years while exhibiting an impressive CAGR. In the years, from 2017 to 2021, market has experienced quite a growth that was counted in millions of sales. The project growth in the forecast period is 2022-2027, on account of a surge in demand for effective with efficient pharmaceutical products. The increasing instances of chronic diseases with complex treatment strategies are demanding the presence of active pharmaceutical ingredients. The Middle East & Africa active pharmaceutical ingredient market in the prominent Countries like Saudi Arabia, UAE, South Africa, have dedicated research labs for advanced products development and consistent product modifications. The Middle East & Africa is expected to witness a low growth over the forecast years due to the lack of awareness about APIs in this region.
The active pharmaceutical ingredient market in the Americas shows a clear north and south divide 88% for the US and Canada, the rest for South and Central American companies. But as the economy in South America booms and prosperity growths One of the fastest growing API markets in the world, with a growing demand for generic and biologic medications. South America API market is one of the markets that are higher CAGR of 5.63% year on year. Markets influenced by the rising population, increased expenditure on health, increased R&D investment in the Pharma Industry are the rise in chronic diseases, less utilisation of generic drugs and government policy towards the API industry.
An active pharmaceutical ingredient is a component of a drug product such as tablet, capsules, cream, syrup, Suspension, Emulsion, Lotion, and injection. Shortage of ibuprofen formulations have seen fall in sales in the active pharmaceutical ingredients market. Supplies of active pharmaceutical ingredient get inspected by their local government. The drug manufacture can sell their medicament under they want with any name but the necessary is to put the active pharmaceutical ingredients name under the brand name. For example Ramipril (to control hypertension) is sale as Ramipril that active pharmaceutical ingredients cannot be bought under another name. The term non-proprietary product which is lacking in proprietary value, not private or privileged information which is distributed without brand name is called non-proprietary drugs i.e public domain Such as Viagra and basically generic drugs which is cheap in cost rather than brand name. And the proprietary products are designed, created, maintained and controlled by the licence agreement related to ownership.
The Active Pharmaceutical Ingredients are the physical, chemical and therapeutically properties are governed by their molecular and their intermolecular interactions that affect the stability and solubility also influences the bioavailability, efficacy and dosage. The active Pharmaceutical ingredients are heavily dominated by china because of the price and technology advantages. In 2015 the government set up expert’s panel that recommend the establishments of active pharmaceuticals ingredients production parks and government incentives for R & D. Asia pacific. Asia pacific including six countries which is china, India Japan, Australia and South Korea
Among product type, high potent APIs segment is expected to witness fastest growth in the global active pharmaceutical ingredient (API) market over the forecast period. Highly potent API (HPAPI) medicines are significant portion of the small molecule therapeutic research pipeline, and this group of products is expanding at faster rate, owing to its use in cancer therapies. For instance, in August 2019, Pfizer CentreOne a global contract development and manufacturing organization (CDMO) introduced high potent drugs to cure cancer, inhibit immune responses to avoid organ rejection, and offer contraception.
Among molecular type, small molecules segment is expected to witness fastest growth over the forecast period in the global active pharmaceutical ingredient (API) market, owing to increasing demand for biologics and increasing approval of small molecule pharmaceuticals. For instance, as per Drug, Chemical & Associated Technologies Association (DCAT), small molecules dominated new drug approvals in 2019, accounting for 79% of all new molecular entity (NME) approvals and representing 38 of the 48 NMEs approved by the U.S. Food and Drug Administration (U.S. FDA) in 2019.
On the basis of formulation, injectable segment is estimated to witness fastest growth in the global active pharmaceutical ingredient (API) market in 2021, owing to regulatory approvals of new injectable molecules. For instance, in January 2020, Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries Ltd., received the S. FDA approval for an autoinjector device for AJOVY (fremanezumab-vfrm) injection. AJOVY is the only U.S. FDA-approved anti-calcitonin gene-related peptide (CGRP) that allows either quarterly (675 mg) or monthly (225 mg) dosage.
In terms of application, cardiovascular segment is expected to witness fastest growth during the forecast period in the global active pharmaceutical ingredient (API) market, owing to increasing prevalence of cardiovascular diseases. For instance, in December 2020, according to American College of Cardiology, cardiovascular diseases (CVD) are the underlying cause of 9.6 million deaths among men and 8.9 million deaths among women. Over 6 million of these deaths occurred in people between the ages of 30-70. The highest number of CVD deaths occurred in China, followed by India, Russia, the U.S., and Indonesia.
Among regions, Asia Pacific is expected to exhibit highest CAGR in the active pharmaceutical ingredient (API) market growth over the forecast period due to lower cost of production, lower labour cost, and high quality based production centers. For instance, as per the China Chamber of Commerce for Import & Export of Medicine and Health products (CCCMHPIE) data, the total active pharmaceutical ingredients produced and exported by China reached 10.1 million tons by volume in 2019.
Major players operating in the global active pharmaceutical ingredient (API) market include Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Dr. Reddy’s Laboratories Ltd., Novartis AG, Mylan N.V., Amneal Pharmaceuticals LLC, Lonza Group, Lupin Limited, Fresenius Kabi, Hikma Pharmaceuticals, Cipla Limited, Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Endo International plc, Aurobindo Pharma Limited, Apotex Inc, Taro Pharmaceutical Industries Ltd, Stada Arzneimittel AG, Krka Pharmaceuticals, CordenPharma International, Evonik Industries AG, and Biological E. Limited.
COVID-19 has highly affected the industries in terms of growth, economy, health, and mental well-being of every individual. In this challenging situation, every industry is trying to give the best services in terms of quality and safety. The outbreak of COVID-19 has affected positively on the healthcare industry and the active pharmaceutical ingredients (API) market. This is due to increased respiratory and infectious disorders in patients. However, due to the outbreak of COVID-19, the funding for the innovation in active pharmaceutical ingredients Active Pharmaceutical Ingredients distracted is the restraining factor for the growth of the global active pharmaceutical ingredients (API) market.
The global Active Pharmaceutical Ingredients market is highly concentrated and competitive. Pfizer, The Cipla, Novartis, Mylan NV, Sun Pharmaceuticals are the prominent vendors in the industry. Over the past decade, several companies have engaged in merger and acquisitions to establish their presence in the industry. Mergers and acquisitions offers several benefits, like, better access to procuring raw materials, distribution and R&D and are largely driven by the consolidation. Manufacturer must always keep pace with the latest industry regulations for the manufacturing Active Pharmaceutical ingredients to avoid penalties with criminal sanctions. The demand for APIs is expected to accelerate because the increase in the geriatric population and increase in awareness for better healthcare. Quality of active pharmaceutical ingredients in a drug has a direct effect on the safety or efficacy of the drugs that are responsible for beneficial health effects on consumers. The most common example of active pharmaceutical ingredient is the acetaminophen and diclofenac containing analgesic drugs.. Excipients must be non-toxic and physically and chemically inert in combination with active pharmaceutical ingredients. Active pharmaceutical ingredients are made not only of a single chemical compound from the raw material but Active Pharmaceutical Ingredients contain several chemical compounds. The intermediate chemical compound which is in the process of becoming active pharmaceutical ingredients from a raw material is called an intermediate.
In North America, Active pharmaceutical Ingredients market is likely to be driven by the adoption of biologics in management, various biological therapeutics, expiration of patent drugs and the outsourcing growth etc. dominated the share of North America market due to growing incidence of severe chronic disease. Ultimately increase in demand of Biological Active Pharmaceutical Ingredients. Raising the number of regulatory approval and increase the R & D, investment moving towards the North America market has increase. In North America according to the country like USA, Canada, and Mexico, Most of the Active pharmaceutical ingredients are manufacture by USA market. USA is doing lot of investments on the advance technology for the manufacturing of Active Pharmaceutical Ingredients.
The Middle East & Africa active pharmaceutical ingredient market is projected to boom in the upcoming years while exhibiting an impressive CAGR. In the years, from 2017 to 2021, market has experienced quite a growth that was counted in millions of sales. The project growth in the forecast period is 2022-2027, on account of a surge in demand for effective with efficient pharmaceutical products. The increasing instances of chronic diseases with complex treatment strategies are demanding the presence of active pharmaceutical ingredients. The Middle East & Africa active pharmaceutical ingredient market in the prominent Countries like Saudi Arabia, UAE, South Africa, have dedicated research labs for advanced products development and consistent product modifications. The Middle East & Africa is expected to witness a low growth over the forecast years due to the lack of awareness about APIs in this region.
The active pharmaceutical ingredient market in the Americas shows a clear north and south divide 88% for the US and Canada, the rest for South and Central American companies. But as the economy in South America booms and prosperity growths One of the fastest growing API markets in the world, with a growing demand for generic and biologic medications. South America API market is one of the markets that are higher CAGR of 5.63% year on year. Markets influenced by the rising population, increased expenditure on health, increased R&D investment in the Pharma Industry are the rise in chronic diseases, less utilisation of generic drugs and government policy towards the API industry.
An active pharmaceutical ingredient is a component of a drug product such as tablet, capsules, cream, syrup, Suspension, Emulsion, Lotion, and injection. Shortage of ibuprofen formulations have seen fall in sales in the active pharmaceutical ingredients market. Supplies of active pharmaceutical ingredient get inspected by their local government. The drug manufacture can sell their medicament under they want with any name but the necessary is to put the active pharmaceutical ingredients name under the brand name. For example Ramipril (to control hypertension) is sale as Ramipril that active pharmaceutical ingredients cannot be bought under another name. The term non-proprietary product which is lacking in proprietary value, not private or privileged information which is distributed without brand name is called non-proprietary drugs i.e public domain Such as Viagra and basically generic drugs which is cheap in cost rather than brand name. And the proprietary products are designed, created, maintained and controlled by the licence agreement related to ownership.
The Active Pharmaceutical Ingredients are the physical, chemical and therapeutically properties are governed by their molecular and their intermolecular interactions that affect the stability and solubility also influences the bioavailability, efficacy and dosage. The active Pharmaceutical ingredients are heavily dominated by china because of the price and technology advantages. In 2015 the government set up expert’s panel that recommend the establishments of active pharmaceuticals ingredients production parks and government incentives for R & D. Asia pacific. Asia pacific including six countries which is china, India Japan, Australia and South Korea
Among product type, high potent APIs segment is expected to witness fastest growth in the global active pharmaceutical ingredient (API) market over the forecast period. Highly potent API (HPAPI) medicines are significant portion of the small molecule therapeutic research pipeline, and this group of products is expanding at faster rate, owing to its use in cancer therapies. For instance, in August 2019, Pfizer CentreOne a global contract development and manufacturing organization (CDMO) introduced high potent drugs to cure cancer, inhibit immune responses to avoid organ rejection, and offer contraception.
Among molecular type, small molecules segment is expected to witness fastest growth over the forecast period in the global active pharmaceutical ingredient (API) market, owing to increasing demand for biologics and increasing approval of small molecule pharmaceuticals. For instance, as per Drug, Chemical & Associated Technologies Association (DCAT), small molecules dominated new drug approvals in 2019, accounting for 79% of all new molecular entity (NME) approvals and representing 38 of the 48 NMEs approved by the U.S. Food and Drug Administration (U.S. FDA) in 2019.
On the basis of formulation, injectable segment is estimated to witness fastest growth in the global active pharmaceutical ingredient (API) market in 2021, owing to regulatory approvals of new injectable molecules. For instance, in January 2020, Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries Ltd., received the S. FDA approval for an autoinjector device for AJOVY (fremanezumab-vfrm) injection. AJOVY is the only U.S. FDA-approved anti-calcitonin gene-related peptide (CGRP) that allows either quarterly (675 mg) or monthly (225 mg) dosage.
In terms of application, cardiovascular segment is expected to witness fastest growth during the forecast period in the global active pharmaceutical ingredient (API) market, owing to increasing prevalence of cardiovascular diseases. For instance, in December 2020, according to American College of Cardiology, cardiovascular diseases (CVD) are the underlying cause of 9.6 million deaths among men and 8.9 million deaths among women. Over 6 million of these deaths occurred in people between the ages of 30-70. The highest number of CVD deaths occurred in China, followed by India, Russia, the U.S., and Indonesia.
Among regions, Asia Pacific is expected to exhibit highest CAGR in the active pharmaceutical ingredient (API) market growth over the forecast period due to lower cost of production, lower labour cost, and high quality based production centers. For instance, as per the China Chamber of Commerce for Import & Export of Medicine and Health products (CCCMHPIE) data, the total active pharmaceutical ingredients produced and exported by China reached 10.1 million tons by volume in 2019.
Major players operating in the global active pharmaceutical ingredient (API) market include Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Dr. Reddy’s Laboratories Ltd., Novartis AG, Mylan N.V., Amneal Pharmaceuticals LLC, Lonza Group, Lupin Limited, Fresenius Kabi, Hikma Pharmaceuticals, Cipla Limited, Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Endo International plc, Aurobindo Pharma Limited, Apotex Inc, Taro Pharmaceutical Industries Ltd, Stada Arzneimittel AG, Krka Pharmaceuticals, CordenPharma International, Evonik Industries AG, and Biological E. Limited.
COVID-19 has highly affected the industries in terms of growth, economy, health, and mental well-being of every individual. In this challenging situation, every industry is trying to give the best services in terms of quality and safety. The outbreak of COVID-19 has affected positively on the healthcare industry and the active pharmaceutical ingredients (API) market. This is due to increased respiratory and infectious disorders in patients. However, due to the outbreak of COVID-19, the funding for the innovation in active pharmaceutical ingredients Active Pharmaceutical Ingredients distracted is the restraining factor for the growth of the global active pharmaceutical ingredients (API) market.
Related Press Releases
Quick Contacts
Trusted Partners
Latest Press Release
We are friendly and approachable, give us a call.